Showing results (121-130 of 792) with videos related to
Sort By:
Pageof 80
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 14, 2008
Perifosine synergistically enhances TRAIL-induced myeloma cell apoptosis via up-regulation of death receptorsEbenezer David, Rajni Sinha, Jing Chen, et al.British Journal of Haematology|July 23, 2011
Monoclonal antibodies in the treatment of multiple myelomaPaul G Richardson, Sagar Lonial, Andrzej J Jakubowiak, et al.Blood|August 25, 2005
The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKTEbenezer David, Shi-Yong Sun, Edmund K Waller, et al.Leukemia|February 22, 2020
Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myelomaAmrita Krishnan, Prashant Kapoor, Joycelynne M Palmer, et al.Expert Review of Hematology|January 30, 2014
Current strategies for treatment of relapsed/refractory multiple myelomaJacob P Laubach, Peter M Voorhees, Hani Hassoun, et al.Nature Reviews. Clinical Oncology|January 22, 2026
Diagnosis, risk stratification and management of smouldering multiple myelomaSaurabh Zanwar, Shaji Kumar, S Vincent RajkumarNucleic Acids Research|December 31, 2005
PINT: Protein-protein Interactions Thermodynamic DatabaseM D Shaji Kumar, M Michael GromihaHaematologica|August 23, 2023
Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myelomaPaul G Richardson, Brian G Durie, Laura Rosiñol, et al.Pharmacological Research|November 26, 2016
Deacetylase inhibitors as a novel modality in the treatment of multiple myelomaPaul G Richardson, Philippe Moreau, Jacob P Laubach, et al.Expert Review of Hematology|September 9, 2017
Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agentPaul Richardson, Anuja Roy, Suddhasatta Acharyya, et al.Pageof 80